WO2025134049 - TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF AL AMYLOIDOSIS
National phase entry is expected:
Publication Number
WO/2025/134049
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063020
International Filing Date
20.12.2024
Title **
[English]
TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF AL AMYLOIDOSIS
[French]
ANTICORPS TRISPÉCIFIQUE CIBLANT BCMA, GPRC5D ET CD3 POUR LE TRAITEMENT DE L'AMYLOSE AL
Applicants **
JANSSEN BIOTECH, INC
Inventors
LEE, Sangmin
DASKALAKIS, Nikki
WEIDMAN, Joseph Warren
NGUYEN, Ashley
VASEY, Sandra Y
TRAN, Namphuong Thi
ELSAYED, Yusri Ali
VERMEULEN, Jessica Tamar
Priority Data
63/613,478
21.12.2023
US
63/660,746
17.06.2024
US
63/695,960
18.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7031 | |
| EPO | Filing, Examination, Granting | 95065 | |
| Japan | Filing, Examination, Granting | 4719 | |
| South Korea | Filing, Examination, Granting | 7180 | |
| USA | Filing, Examination, Granting | 22990 |
Total:
136,985
Contact Us
Abstract[English]
Embodiments of the present disclosure relate to methods of treating AL amyloidosis in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, to the subject to the subject to treat the AL amyloidosis.[French]
Des modes de réalisation de la présente divulgation concernent des méthodes de traitement de l'amylose AL chez un sujet en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace d'un anticorps trispécifique de BCMA x GPRC5D x CD3 ou d'un fragment de liaison trispécifique de celui-ci, au sujet, pour traiter l'amylose AL.